Ethionamide versus ethambutol-containing first-line regimens for TB meningitis
Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)
DOI: 10.1128/aac.00190-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Xueyi Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Ethambutol, Tuberculosis, Meningeal, Antitubercular Agents, Ethionamide. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Ethionamide has emerged as an alternative to ethambutol for the treatment of tuberculous meningitis (TB meningitis). Here, we show that ethionamide- and ethambutol-containing first-line TB regimens achieved similar bactericidal activities in brain tissues and reduction in neuroinflammation in a mouse model of TB meningitis. However, ethionamide, but not ethambutol, achieves brain concentrations above the minimum inhibitory concentration for Mycobacterium tuberculosis .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
ORCID-Profile: Xueyi Chen, Sanjay K Jain
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Chen, X., Ruiz-Gonzalez, C. E., Masias-Leon, Y., Singh, M., Shambles, M., Peloquin, C. A., & Jain, S. K. (2026). Ethionamide versus ethambutol-containing first-line regimens for TB meningitis. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00190-26
Vancouver
Chen X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, Shambles M, Peloquin CA, et al. Ethionamide versus ethambutol-containing first-line regimens for TB meningitis. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00190-26
BibTeX
@article{Chen2026,
author = {Chen, Xueyi and Ruiz-Gonzalez, Carlos E and Masias-Leon, Yuderleys and Singh, Medha and Shambles, Madelynn and Peloquin, Charles A and Jain, Sanjay K},
title = {Ethionamide versus ethambutol-containing first-line regimens for TB meningitis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {8},
doi = {10.1128/aac.00190-26}
}
EUVIMED